Barclays Issues Positive Forecast for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price

Iovance Biotherapeutics (NASDAQ:IOVA) had its target price upped by Barclays from $18.00 to $19.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

A number of other research analysts also recently commented on the company. Citizens Jmp upped their price objective on Iovance Biotherapeutics from $8.00 to $12.00 and gave the stock a “market outperform” rating in a research note on Friday. Zacks Research upgraded shares of Iovance Biotherapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 26th. The Goldman Sachs Group started coverage on shares of Iovance Biotherapeutics in a research note on Thursday, September 24th. They set a “buy” rating and a $15.00 price objective for the company. HC Wainwright raised their target price on Iovance Biotherapeutics from $9.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Finally, UBS Group upped their price objective on shares of Iovance Biotherapeutics from $7.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $13.80.

Iovance Biotherapeutics Stock Performance

Shares of IOVA traded up $0.30 during trading hours on Friday, hitting $8.04. The stock had a trading volume of 12,935,434 shares, compared to its average volume of 15,291,578. Iovance Biotherapeutics has a 12-month low of $2.08 and a 12-month high of $15.37. The company’s fifty day simple moving average is $11.37 and its 200 day simple moving average is $5.97. The firm has a market cap of $3.64 billion, a P/E ratio of -15.17 and a beta of 0.88.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The firm had revenue of $121.47 million during the quarter, compared to analysts’ expectations of $115.98 million. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. Iovance Biotherapeutics’s revenue for the quarter was up 64.8% on a year-over-year basis. As a group, sell-side analysts predict that Iovance Biotherapeutics will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several large investors have recently made changes to their positions in IOVA. Clearwater Capital Advisors LLC acquired a new stake in shares of Iovance Biotherapeutics in the third quarter worth $322,000. Russell Investments Group Ltd. lifted its position in shares of Iovance Biotherapeutics by 165.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 513,032 shares of the biotechnology company’s stock worth $7,603,000 after buying an additional 319,979 shares during the period. Brighton Jones LLC boosted its stake in shares of Iovance Biotherapeutics by 5.1% in the 3rd quarter. Brighton Jones LLC now owns 40,069 shares of the biotechnology company’s stock valued at $594,000 after purchasing an additional 1,954 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in Iovance Biotherapeutics by 867.6% in the third quarter. Pictet Asset Management Holding SA now owns 416,539 shares of the biotechnology company’s stock valued at $6,043,000 after buying an additional 373,491 shares in the last quarter. Finally, Kestra Advisory Services LLC grew its position in Iovance Biotherapeutics by 25.2% during the 3rd quarter. Kestra Advisory Services LLC now owns 42,150 shares of the biotechnology company’s stock worth $625,000 after acquiring an additional 8,483 shares during the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported record third-quarter revenue of about $122 million, beating estimates, while its loss of $0.05 per share was narrower than the expected $0.09. Amtagvi U.S. revenue grew about 77% year over year, gross margin reached a company-record 60%, and management reaffirmed its 2026 revenue outlook. These results point to growing commercial traction and improving economics. Iovance third-quarter results
• Positive Sentiment: Barclays raised its price target from $18 to $19 and kept an “overweight” rating; Citizens JMP raised its target from $8 to $12 and maintained a “market outperform” rating. The upgrades reflect more optimistic analyst views on IOVA’s prospects. Barclays ratings Citizens JMP ratings
• Positive Sentiment: Lifileucel received FDA Fast Track designation following promising sarcoma trial data, potentially supporting development in an additional cancer indication. Lifileucel Fast Track news
• Negative Sentiment: NSCLC results were mixed: the objective response rate was 24.6% across 69 evaluable patients, slightly below a prior interim result. That may temper expectations for this opportunity, although a biomarker-selected subgroup showed a higher 59.1% response rate and a trial is underway. Iovance clinical outlook

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.